%0 Journal Article
%A Lodde, Georg Christian
%A Krefting, Frederik
%A Placke, Jan-Malte
%A Schneider, Lea
%A Fiedler, Melanie
%A Dittmer, Ulf
%A Becker, Jürgen
%A Hölsken, Stefanie
%A Schadendorf, Dirk
%A Ugurel, Selma
%A Sondermann, Wiebke
%T COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study.
%J Frontiers in immunology
%V 14
%@ 1664-3224
%C Lausanne
%I Frontiers Media
%M DKFZ-2023-00679
%P 1107438
%D 2023
%X The rate of seroconversion after COVID-19 vaccination in patients with moderate to severe psoriasis requiring systemic treatment is poorly understood.The aim of this prospective single-center cohort study performed between May 2020 and October 2021 was to determine the rate of seroconversion after COVID-19 vaccination in patients under active systemic treatment for moderate to severe psoriasis.Inclusion criteria were systemic treatment for moderate to severe psoriasis, known COVID-19 vaccination status, and repetitive anti-SARS-CoV-2-S IgG serum quantification. The primary outcome was the rate of anti-SARS-CoV-2-S IgG seroconversion after complete COVID-19 vaccination.77 patients with a median age of 55.9 years undergoing systemic treatment for moderate to severe psoriasis were included. The majority of patients received interleukin- (n=50, 64.9
%K COVID-19 vaccines (Other)
%K biologics (Other)
%K psoriasis (Other)
%K psoriasis treatment (Other)
%K seroconversion (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37006279
%2 pmc:PMC10061348
%R 10.3389/fimmu.2023.1107438
%U https://inrepo02.dkfz.de/record/275221